146 related articles for article (PubMed ID: 14638468)
1. In vivo efficacy of a new quinolone, DQ-113, against Streptococcus pneumoniae in a mouse model.
Otsu Y; Yanagihara K; Fukuda Y; Miyazaki Y; Tsukamoto K; Hirakata Y; Tomono K; Kadota J; Tashiro T; Murata I; Kohno S
Antimicrob Agents Chemother; 2003 Dec; 47(12):3699-703. PubMed ID: 14638468
[TBL] [Abstract][Full Text] [Related]
2. In vivo efficacies and pharmacokinetics of DX-619, a novel des-fluoro(6) quinolone, against Streptococcus pneumoniae in a mouse lung infection model.
Fukuda Y; Yanagihara K; Ohno H; Higashiyama Y; Miyazaki Y; Tsukamoto K; Hirakata Y; Tomono K; Mizuta Y; Tashiro T; Kohno S
Antimicrob Agents Chemother; 2006 Jan; 50(1):121-5. PubMed ID: 16377676
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone.
Otani T; Tanaka M; Ito E; Kurosaka Y; Murakami Y; Onodera K; Akasaka T; Sato K
Antimicrob Agents Chemother; 2003 Dec; 47(12):3750-9. PubMed ID: 14638477
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics and bactericidal activity of gatifloxacin in experimental pneumonia caused by penicillin-resistant Streptococcus pneumoniae.
Yanagihara K; Fukuda Y; Miyazaki Y; Tsukamoto K; Hirakata Y; Tomono K; Kadota J; Tashiro T; Murata I; Kohno S
Chemotherapy; 2004 Jun; 50(3):107-12. PubMed ID: 15282438
[TBL] [Abstract][Full Text] [Related]
5. In vivo efficacy of a new fluoroquinolone, sparfloxacin, against penicillin-susceptible and -resistant and multiresistant strains of Streptococcus pneumoniae in a mouse model of pneumonia.
Azoulay-Dupuis E; Vallee E; Veber B; Bedos JP; Bauchet J; Pocidalo JJ
Antimicrob Agents Chemother; 1992 Dec; 36(12):2698-703. PubMed ID: 1336343
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models.
Andes D; Craig WA
Antimicrob Agents Chemother; 2002 Jun; 46(6):1665-70. PubMed ID: 12019073
[TBL] [Abstract][Full Text] [Related]
7. [Alteration of antibacterial activity of tosufloxacin and various antibacterial agents against Streptococcus pneumoniae].
Maekawa M; Fukuda Y; Sugiura Y; Kamiyama T; Futakuchi N; Takahata M; Mitsuyama J
Jpn J Antibiot; 2003 Feb; 56(1):27-35. PubMed ID: 12723396
[TBL] [Abstract][Full Text] [Related]
8. Effects of DQ-113, a new quinolone, against methicillin- and vancomycin-resistant Staphylococcus aureus-caused hematogenous pulmonary infections in mice.
Kaneko Y; Yanagihara K; Miyazaki Y; Tsukamoto K; Hirakata Y; Tomono K; Kadota J; Tashiro T; Murata I; Kohno S
Antimicrob Agents Chemother; 2003 Dec; 47(12):3694-8. PubMed ID: 14638467
[TBL] [Abstract][Full Text] [Related]
9. Ceftaroline versus ceftriaxone in a highly penicillin-resistant pneumococcal pneumonia rabbit model using simulated human dosing.
Croisier-Bertin D; Piroth L; Charles PE; Larribeau A; Biek D; Ge Y; Chavanet P
Antimicrob Agents Chemother; 2011 Jul; 55(7):3557-63. PubMed ID: 21576444
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics of the new des-f(6)-quinolone garenoxacin in a murine thigh infection model.
Andes D; Craig WA
Antimicrob Agents Chemother; 2003 Dec; 47(12):3935-41. PubMed ID: 14638504
[TBL] [Abstract][Full Text] [Related]
11. Activity of tedizolid phosphate (TR-701) in murine models of infection with penicillin-resistant and penicillin-sensitive Streptococcus pneumoniae.
Choi S; Im W; Bartizal K
Antimicrob Agents Chemother; 2012 Sep; 56(9):4713-7. PubMed ID: 22713339
[TBL] [Abstract][Full Text] [Related]
12. [In vitro and in vivo activities of cefpodoxime proxetil against penicillin-resistant Streptococcus pneumoniae].
Kawada H; Kitayama A; Fukuoka T; Ishii C; Abe T; Kakuta M; Domon H; Ohya S; Utsui Y
Jpn J Antibiot; 1999 Aug; 52(8):533-40. PubMed ID: 10587878
[TBL] [Abstract][Full Text] [Related]
13. [In vitro and in vivo activities of panipenem against penicillin-resistant Streptococcus pneumoniae].
Fukuoka T; Inoue H; Abe T; Ohya S
Jpn J Antibiot; 2001 Jul; 54(7):365-71. PubMed ID: 11560055
[TBL] [Abstract][Full Text] [Related]
14. In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants.
Croisier D; Etienne M; Piroth L; Bergoin E; Lequeu C; Portier H; Chavanet P
J Antimicrob Chemother; 2004 Sep; 54(3):640-7. PubMed ID: 15317743
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic effect of oral levofloxacin, ciprofloxacin, and ampicillin on experimental murine pneumonia caused by penicillin intermediate Streptococcus pneumoniae for which the minimum inhibitory concentrations of the quinolones are similar.
Ishida Y; Kurosaka Y; Murakami Y; Otani T; Yamaguchi K
Chemotherapy; 1999; 45(3):183-91. PubMed ID: 10224340
[TBL] [Abstract][Full Text] [Related]
16. Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model.
Hershberger E; Rybak MJ
Antimicrob Agents Chemother; 2000 Mar; 44(3):598-601. PubMed ID: 10681324
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic activities of ciprofloxacin and sparfloxacin in a murine pneumococcal pneumonia model: relevance for drug efficacy.
Bédos JP; Azoulay-Dupuis E; Moine P; Muffat-Joly M; Veber B; Pocidalo JJ; Vallée E
J Pharmacol Exp Ther; 1998 Jul; 286(1):29-35. PubMed ID: 9655838
[TBL] [Abstract][Full Text] [Related]
18. Antibacterial activity of AM-1155 against penicillin-resistant Streptococcus pneumoniae.
Tomizawa H; Tateda K; Miyazaki S; Yamaguchi K
J Antimicrob Chemother; 1998 Jan; 41(1):103-6. PubMed ID: 9511043
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo antibacterial activities of DC-159a, a new fluoroquinolone.
Hoshino K; Inoue K; Murakami Y; Kurosaka Y; Namba K; Kashimoto Y; Uoyama S; Okumura R; Higuchi S; Otani T
Antimicrob Agents Chemother; 2008 Jan; 52(1):65-76. PubMed ID: 17938194
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamics of levofloxacin and ciprofloxacin in a murine pneumonia model: peak concentration/MIC versus area under the curve/MIC ratios.
Scaglione F; Mouton JW; Mattina R; Fraschini F
Antimicrob Agents Chemother; 2003 Sep; 47(9):2749-55. PubMed ID: 12936969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
